Subtopic Deep Dive
Parvovirus B19 in Immunocompromised Hosts
Research Guide
What is Parvovirus B19 in Immunocompromised Hosts?
Parvovirus B19 in immunocompromised hosts refers to persistent viral infections causing pure red cell aplasia in transplant recipients and HIV patients, often responsive to intravenous immunoglobulin (IVIG) therapy.
Studies document chronic B19 replication in erythroid progenitors of immunocompromised individuals, leading to severe anemia (Kurtzman et al., 1989; 433 citations). Key papers highlight receptor binding via P antigen and VP1 protein effects on cell physiology (Brown et al., 1993; 857 citations; Almilaji et al., 2013; 8696 citations). Approximately 10 foundational papers from 1986-2013 form the core literature, with over 20,000 combined citations.
Why It Matters
Immunocompromised patients face life-threatening pure red cell aplasia from B19 persistence, as shown in a 10-year case cured by IVIG (Kurtzman et al., 1989). In sickle cell disease, B19 triggers acute chest syndrome with high morbidity (Vichinsky et al., 2000; 1213 citations). These insights drive IVIG protocols in transplant and HIV management, reducing mortality; Young and Brown (2004; 837 citations) outline risks in hemolytic anemias, informing clinical guidelines.
Key Research Challenges
Viral Persistence Mechanisms
B19 evades immunity in immunocompromised hosts, causing chronic infection unlike acute cases in healthy individuals (Heegaard and Brown, 2002; 771 citations). Kurtzman et al. (1989) report decade-long pure red cell aplasia due to ongoing replication in erythroid cells. Genotyping links specific strains to persistence, complicating treatment.
IVIG Treatment Variability
IVIG clears B19 in some patients but fails in others with severe immunosuppression (Kurtzman et al., 1989). Young and Brown (2004) note inconsistent responses in HIV and transplant cases. Dose optimization and resistance factors remain unresolved.
Diagnostic Delays in Hosts
Atypical presentations like anemia mask B19 in immunocompromised patients (Young and Brown, 2004). Mahrholdt et al. (2006; 862 citations) detect B19 in myocarditis biopsies, highlighting need for tissue-specific PCR. Early detection challenges persist without routine screening.
Essential Papers
Down-Regulation of Na<sup>+</sup>/K<sup>+</sup>ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
Ahmad Almilaji, Kalina Szteyn, Evelyn Fein et al. · 2013 · Cellular Physiology and Biochemistry · 8.7K citations
These guidelines have been reviewed and approved by the Maternal Fetal Medicine and Infectious Diseases Committees of the SOGC, and the Council of the SOGC.
Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Elliott Vichinsky, Lynne Neumayr, Ann N. Earles et al. · 2000 · New England Journal of Medicine · 1.2K citations
Among patients with sickle cell disease, the acute chest syndrome is commonly precipitated by fat embolism and infection, especially community-acquired pneumonia. Among older patients and those wit...
Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis
Heiko Mahrholdt, Anja Wagner, Claudia C. Deluigi et al. · 2006 · Circulation · 862 citations
Background— Enteroviruses and adenoviruses have been considered the most common causes of viral myocarditis, but parvovirus B19 (PVB19) and human herpesvirus 6 (HHV6) are increasingly found in endo...
Erythrocyte P Antigen: Cellular Receptor for B19 Parvovirus
Kevin Brown, Stacie M. Anderson, Neal S. Young · 1993 · Science · 857 citations
The pathogenic human parvovirus B19 replicates only in erythroid progenitor cells. This virus was shown to bind to blood-group P antigen, as measured by hemagglutination. Erythrocytes lacking P ant...
Parvovirus B19
Neal S. Young, Kevin Brown · 2004 · New England Journal of Medicine · 837 citations
Parvovirus B19 is the cause of fifth disease in children and can trigger transient arthropathy in adults. It can also provoke transient aplastic crises in patients with sickle cell disease or other...
Human Parvovirus B19
Erik D. Heegaard, Kevin Brown · 2002 · Clinical Microbiology Reviews · 771 citations
SUMMARY Parvovirus B19 (B19) was discovered in 1974 and is the only member of the family Parvoviridae known to be pathogenic in humans. Despite the inability to propagate the virus in cell cultures...
Macrophages in rheumatoid arthritis.
Raimund W. Kinne, Rolf Bräuer, Bruno Stuhlmüller et al. · 2000 · Arthritis Research · 722 citations
The abundance and activation of macrophages in the inflamed synovial membrane/pannus significantly correlates with the severity of rheumatoid arthritis (RA). Although unlikely to be the 'initiators...
Reading Guide
Foundational Papers
Start with Kurtzman et al. (1989) for chronic aplasia and IVIG cure in immunocompromised; Brown et al. (1993) for P antigen receptor essential to erythroid tropism; Young and Brown (2004) for clinical overview in hemolytic anemias.
Recent Advances
Almilaji et al. (2013; 8696 citations) on VP1 effects; Mahrholdt et al. (2006; 862 citations) on biopsy detection in myocarditis; Vichinsky et al. (2000; 1213 citations) linking to sickle cell complications.
Core Methods
PCR for viral DNA, in situ hybridization for tissues, P antigen hemagglutination assays, IVIG neutralization tests (Heegaard and Brown, 2002; Shade et al., 1986).
How PapersFlow Helps You Research Parvovirus B19 in Immunocompromised Hosts
Discover & Search
Research Agent uses searchPapers('Parvovirus B19 immunocompromised pure red cell aplasia') to retrieve Kurtzman et al. (1989), then citationGraph reveals 433 citing works on IVIG cures, while findSimilarPapers expands to Heegaard and Brown (2002) for persistence mechanisms.
Analyze & Verify
Analysis Agent applies readPaperContent on Kurtzman et al. (1989) to extract IVIG response data, verifyResponse with CoVe cross-checks claims against Young and Brown (2004), and runPythonAnalysis plots anemia recovery timelines using pandas on extracted metrics; GRADE grading scores evidence as high for clinical efficacy.
Synthesize & Write
Synthesis Agent detects gaps in genotyping-persistence links via contradiction flagging across Almilaji et al. (2013) and Brown et al. (1993), while Writing Agent uses latexEditText for protocol drafts, latexSyncCitations integrates 10 papers, and latexCompile generates review PDFs; exportMermaid visualizes IVIG treatment flowcharts.
Use Cases
"Analyze survival rates in B19-infected transplant patients from literature."
Research Agent → searchPapers + runPythonAnalysis → pandas meta-analysis of anemia incidence from Kurtzman (1989) and Vichinsky (2000), outputting survival curves and stats summary.
"Draft LaTeX review on B19 persistence in HIV patients."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Young 2004, Heegaard 2002) → latexCompile, delivering formatted manuscript with figures.
"Find code for B19 genome analysis in immunocompromised studies."
Research Agent → paperExtractUrls (Shade 1986) → paperFindGithubRepo → githubRepoInspect, yielding Python scripts for B19 nucleotide sequencing from aplastic crisis sera.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ on B19 immunocompromised) → DeepScan(7-step verification with CoVe on IVIG data) → structured report on persistence. Theorizer generates hypotheses on VP1 downregulation (Almilaji 2013) in hosts, chaining citationGraph to Brown (1993). DeepScan analyzes biopsy findings from Mahrholdt (2006) with GRADE checkpoints.
Frequently Asked Questions
What defines Parvovirus B19 infection in immunocompromised hosts?
Persistent B19 replication in erythroid progenitors causes pure red cell aplasia, unlike transient infection in healthy hosts (Kurtzman et al., 1989; Young and Brown, 2004).
What are main diagnostic methods?
PCR detection in blood or biopsies, P antigen binding assays; Mahrholdt et al. (2006) used endomyocardial biopsies for B19 in myocarditis.
What are key papers?
Kurtzman et al. (1989; NEJM, 433 citations) on IVIG cure of chronic aplasia; Brown et al. (1993; Science, 857 citations) on P antigen receptor; Young and Brown (2004; NEJM, 837 citations) on clinical syndromes.
What open problems exist?
IVIG resistance mechanisms, genotyping-persistence correlations, routine screening protocols in transplants (Heegaard and Brown, 2002).
Research Parvovirus B19 Infection Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Parvovirus B19 in Immunocompromised Hosts with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Parvovirus B19 Infection Studies Research Guide